Reply to M. Horiguchi et al

Affiliations

¹ Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Joel Jiang and Thomas Kelleher, Bristol-Myers Squibb, Princeton, NJ; and Michael A. Postow, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

Comment

Dirk Schadendorf et al. J Clin Oncol. 2018.

. 2018 Mar 1;36(7):721.

doi: 10.1200/JCO.2017.76.5339. Epub 2018 Jan 16.

¹ Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Joel Jiang and Thomas Kelleher, Bristol-Myers Squibb, Princeton, NJ; and Michael A. Postow, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

No abstract available

Comment on

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA. Schadendorf D, et al. J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25. J Clin Oncol. 2017. PMID: 28841387 Free PMC article.
Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
Horiguchi M, Uno H, Wei LJ. Horiguchi M, et al. J Clin Oncol. 2018 Mar 1;36(7):720-721. doi: 10.1200/JCO.2017.76.0983. Epub 2018 Jan 16. J Clin Oncol. 2018. PMID: 29337638 No abstract available.